Patrick Brown: Is Blinatumomab a New Standard of Care for Young Patients With B-Cell ALL?

Patrick A. Brown, MD, discusses the results seen with blinatumomab as consolidation therapy in young patients with higher-risk, relapsed B-cell acute lymphocytic leukemia, where it improved relapse-free survival by 20%, compared with standard chemotherapy.

SHARE